Tauopathies with parkinsonism: Clinical spectrum, neuropathologic basis, biological markers, and treatment options

Department of Neurology, University of Ulm, Ulm, Germany.
European Journal of Neurology (Impact Factor: 3.85). 04/2009; 16(3):297-309. DOI: 10.1111/j.1468-1331.2008.02513.x
Source: PubMed

ABSTRACT Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system. These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic interventions. Natural history studies, for instance, in progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17, corticobasal degeneration, and Niemann-Pick disease type C as well as in amyotrophic lateral sclerosis/Parkinson-dementia complex permit clinical characterization of the disease phenotypes and are crucial to the development and validation of biological markers for differential diagnostics and disease monitoring, for example, by use of neuroimaging or proteomic approaches. The wide pathologic and clinical spectrum of the tauopathies with parkinsonism is reviewed in this article, and perspectives on future advances in the understanding of the pathogenesis are given, together with potential therapeutic strategies.

Download full-text


Available from: Zygmunt Jamrozik, Aug 25, 2015
  • Source
    • "Tauopathies are a broad class of neurodegenerative diseases characterized by aggregates of protein Tau in different regions and types of neurons, the basis of postmortem diagnosis and differentiation (for review, see Delacourte and Buée, 2000; Ingram and Spillantini, 2002; Duyckaerts et al., 2009; Ludolph et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive demise correlates with progressive brain tauopathy in dementing patients. Improved cognition of young Tau.P301L mice contrasts with dysfunction later in life and remains unexplained (Boekhoorn et al., 2006). To unravel early mechanisms, we composed a correlative time line of clinical symptoms, cognitive defects, and biochemical and pathological traits, including comprehensive analysis of dendritic spines in specified regions of the cortex and hippocampus of young and adult Tau.P301L mice. Remarkably, young Tau.P301L mice have not more, but more mature spines than wild-type mice, revealing the anatomical substrate for their improved cognition and LTP. Spine maturation remained high in the hippocampus of adult Tau.P301L mice. However, spines regressed in length paralleling impaired cognition and increased Tau phosphorylation (Terwel et al., 2005). Conversely, spine maturation was unaffected in adult Tau.4R mice, while spine density was increased and length reduced similar to Tau.P301L mice. To explain how protein Tau promoted spinogenesis, we analyzed hippocampal synaptosomes and dendritic spines for mouse and human Tau. While synaptosomes were positive for both mouse and human Tau, weak variable reaction in spines was observed only after fixation according to Bouin. Mouse Tau was absent from spines in wild-type mice, dissociating the pathological actions of Tau in transgenic mice by relocalization into dendrites and spines from the physiological actions of protein Tau in axons only. We conclude that mutant protein Tau modulates cognition and morphology of spines similarly and in both directions, with pathology later in life coinciding with increased phosphorylation and relocalization of Tau from axons to soma and processes.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 12/2011; 31(49):18036-47. DOI:10.1523/JNEUROSCI.4859-11.2011 · 6.75 Impact Factor
  • Source
    • "Corticobasal degeneration (CBD) is a neuropathologic diagnosis characterized by atrophy, gliosis, and tau-immunoreactive pathology in the neocortex, basal ganglia, and substantia nigra (Ludolph et al., 2009). Historically, CBD was considered to be a distinct clinicopathologic entity presenting with CBS (Rebeiz, Kolodny, & Richardson, 1968), but it is now understood that CBD frequently presents in other clinical syndromes, most often bvFTD and PNFA (Boeve, 2007a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Visual spatial impairment is often an early symptom of neurodegenerative disease; however, this multi-faceted domain of cognition is not well-assessed by most typical dementia evaluations. Neurodegenerative diseases cause circumscribed atrophy in distinct neural networks, and accordingly, they impact visual spatial cognition in different and characteristic ways. Anatomically-focused visual spatial assessment can assist the clinician in making an early and accurate diagnosis. This article will review the literature on visual spatial cognition in neurodegenerative disease clinical syndromes, and where research is available, by neuropathologic diagnoses. Visual spatial cognition will be organized primarily according to the following schemes: bottom-up/top-down processing, dorsal/ventral stream processing, and egocentric/allocentric frames of reference.
    Neurocase 12/2010; 16(6):466-87. DOI:10.1080/13554791003730600 · 1.38 Impact Factor
  • Source
    • "Cells exhibit differential vulnerability to abnormalities of protein metabolism resulting in protein-specific regional dysfunction, and the topography of the cellular dysfunction, in turn, determines the clinical phenotype.... " . In other words, each etiological form of degenerative dementia is characterized by the deposition of a specific altered protein in a particular region (or regions) of the brain (e.g., Kovacs et al. 2010; Rademakers and Rovelet-Lecrux 2009; Ludolph et al. 2009) and the clinical, behavioral, and neuropsychological manifestations of a particular form of dementia depend strictly on the specific cortical and/or subcortical area in which the protein deposition occurs or is at least prevalent (e.g., Rascovsky et al. 2002; Grossman et al. 2007; Davies et al. 2005; Kraybill et al. 2005). When applied to the issue of differential diagnosis of degenerative dementias, one corollary of the " selective regional vulnerability " principle is that the selectivity of the regional involvement is particularly stringent in the very early phases of the degenerative process. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the present review paper was to evaluate the hypothesis (included in the proposal of new research criteria for Alzheimer's disease; Dubois et al., Lancet Neurology, 6, 734-746, 2007) that a neuropsychological tool which provides support for the semantic encoding of memorandum at the time of study and supplies category cues at the time of retrieval (i.e. the Grober-Buschke paradigm) is more effective than traditional measures of free recall in 1) differentiating patients affected by the amnestic form of Mild Cognitive Impairment (MCI) or by mild to moderate forms of Alzheimer's disease (AD) from healthy matches, 2) predicting the conversion of individuals with MCI to AD, and 3) differentiating AD patients from individuals affected by other forms of dementia. Results of the review are controversial regarding the superiority of the Grober-Buschke procedure in differentiating individuals affected by AD or MCI from healthy individuals. The only study that evaluated this issue directly found that the Grober-Buschke procedure was more sensitive and specific than more traditional memory tests in predicting the conversion of MCI patients to AD. Finally, two studies reported that patients affected by AD or other forms of dementia showed different performance patterns in the free and cued recall tasks of the Grober-Buschke procedure. In conclusion, although encouraging results are reported in the few studies that investigated the ability of this procedure to predict the evolution of individuals with amnestic MCI and to differentiate AD patients from patients with other forms of cortical and subcortical dementia, more experimental work is needed to confirm these positive findings.
    Neuropsychology Review 11/2010; 21(1):54-65. DOI:10.1007/s11065-010-9153-7 · 5.40 Impact Factor
Show more